Trial Profile
Lipid-Altering Efficacy and Safety Profile of Co-Administered Extended Release Niacin/Laropiprant and Simvastatin Versus Atorvastatin in Patients With Mixed Hyperlipidemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2015
Price :
$35
*
At a glance
- Drugs Niacin/laropiprant (Primary) ; Simvastatin (Primary) ; Atorvastatin
- Indications Hyperlipidaemia
- Focus Therapeutic Use
- 05 Dec 2011 New trial record
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.